Sutro Biopharma, Inc. (S09.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Add to watchlist

6.65

+0.10

(+1.53%)

At close: 09:15AM CET

Loading interactive chart...

Simply Wall St.
Are Investors Undervaluing Sutro Biopharma, Inc. (NASDAQ:STRO) By 46%?
In this article we are going to estimate the intrinsic value of Sutro Biopharma, Inc. ( NASDAQ:STRO ) by estimating the...
GlobeNewswire
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
- Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at the higher starting dose of 5.2mg/kg - - Meaningful clinical benefit was observed in FolRα-selected patients, defined as TPS>25%, which is potentially 80% of the advanced ovarian cancer patient population - - Safety profile is generally consistent with prior data with asymptom
Simply Wall St.
With 74% ownership of the shares, Sutro Biopharma, Inc. (NASDAQ:STRO) is heavily dominated by institutional owners
If you want to know who really controls Sutro Biopharma, Inc. ( NASDAQ:STRO ), then you'll have to look at the makeup...